🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New Research: A phase 3 trial assessing NeuroSAFE-guided robot-assisted radical prostatectomy vs standard robot-assisted radical prostatectomy in #prostatecancer for nerve-sparing surgery and erectile function recovery bit.ly/4iBzF7C

👋 Introducing The Lancet Obstetrics, Gynaecology, & Women’s Health, a new journal dedicated to bridging clinical evidence and practice to transform the lives of women. Find out more ➡️ hubs.li/Q03dDDXP0 #womenshealth #obgyn

News: Concern for cancer drugs in USA–EU #tariffs war “We expect the pharmaceutical companies not to let this chaos over trade go to waste and try to raise prices while pointing the finger at tariffs.” - Merith Basey (Patients for Affordable Drugs) thelancet.com/journals/lanon…

News: Talha Burki reports on the destruction of Gaza's Turkish–Palestinian Friendship Hospital (March 21) “Curable cancers become incurable, local cancers metastasize, and the pain goes unrelieved” - Sobhi Skaik (TPFH, Gaza) thelancet.com/journals/lanon…

🔦 Our editorial calls for a global cancer funding collaboration in light of new policy changes bit.ly/3FPiXmI 📢 We interview Amar Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA) in our In Conversation With podcast bit.ly/43AqmjB

Neurological problems are a significant concern for patients receiving CAR T-cell therapy, yet there are no best practice guidelines. In The Lancet Oncology, a Review provides guidance on managing neurological issues associated with CAR T-cell therapy: hubs.li/Q03fg2Wn0

Online today: The Global Platform for Access to Childhood Cancer Medicines: addressing inequities in childhood cancer care Tedros Adhanom Ghebreyesus and James R Downing discuss the World Health Organization (WHO) and St. Jude Global Platform for Access to Childhood Cancer Medicines thelancet.com/journals/lanon…

Policy review: ACCELERATE report an analysis on the development and access to CAR T-cell therapies for children and adolescents with cancer bit.ly/4laqaxI

News: Sharmila Devi reports on the US cuts to the Health and Human Services Department (HHS), reduction of federal grant funding for indirect costs, and cuts to cancer research thelancet.com/journals/lanon…

#Adrenocortical #carcinoma poses unique challenges to physicians, who must tackle both tumour progression and hormone secretion, and it considerably affects life expectancy thelancet.com/journals/landi… #adrenal #OpenAccess

Pancreatic cancer, often linked to smoking, obesity and diabetes, is predicted to become the 2nd leading cause of cancer-related death by 2030. A new Seminar discusses the need for novel therapies & future directions for research: hubs.li/Q03fW9vm0

Review: Antonin Levy, Christophe Massard, Stefan Michiels, and Eric Deutsch highlight the latest developments and future directions for early-phase clinical trials that combine precision drug–radiotherapy strategies #radiotherapy thelancet.com/journals/lanon…

A thought-provoking discussion on the new Common Sense Oncology checklist for designing and reporting cancer drug RCTs! A true game-changer for pragmatic, patient-centered oncology—redefining what really matters in global cancer research. Bishal Gyawali, MD, PhD, FASCO Journal of Clinical Oncology The Lancet Oncology Ontario Institute for Cancer Research (OICR)

Online: The final analysis of the phase 3 ALCYONE study assessing the addition of daratumumab to bortezomib, melphalan, and prednisone for patients with newly diagnosed #multiplemyeloma thelancet.com/journals/lanon…

See our paper today in The Lancet Oncology highlighting the mismanagement of cancer for the last 14 years and the need to get real . We are in crisis and we need to act without delay. Lets be Leaders not Laggers qub.ac.uk/News/Allnews/2… dailymail.co.uk/news/article-1…

Online first: highlights from an EU Medicines Agency EORTC workshop: using patient-reported outcomes and #QoL data in regulatory decisions 📰Perspective: thelancet.com/journals/lanon… 📝Comment: thelancet.com/journals/lanon…

📢 New publication in The Lancet Oncology summarises the highlights from a joint EMA–EORTC workshop that looked at the role of patient-reported outcomes (PROs) in cancer treatment evaluation. 🔗 Read more in our press release: eortc.org/blog/2025/04/1… #CancerResearch #QualityofLife